Genfit Announces Voluntary Withdrawal of its ADS from Nasdaq
The biopharmaceutical company GENFIT (Euronext and Nasdaq: GNFT) announces that the voluntary withdrawal of its American Depositary Shares (ADS) from the Nasdaq Global Select Market is now effective. Each ADS represented one ordinary share of the company.
Following this action, GENFIT has filed a Form 15F with the Securities and Exchange Commission (SEC) to suspend its reporting obligations in the United States. The deregistration of the ADS under the Securities Exchange Act is expected to occur within 90 days.
The ADS program, managed by The Bank of New York Mellon, will be terminated as of February 6, 2026. ADS holders have until February 9, 2026, to return their securities and request the delivery of the underlying ordinary shares. Conversion and cancellation fees apply. After this deadline, the depository may sell the unclaimed ordinary shares and distribute the net proceeds of the sale to the holders.
GENFIT remains listed on Euronext Paris under the same symbol, GNFT.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 1T2026
Key reported figures
Revenue: 9.6M€
Risks mentioned
Dépendance aux partenaires pour le développement commercial.
Opportunities identified
Dynamique favorable des ventes d'Iqirvo renforçant les marges financières.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
